GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amniotics AB (OSTO:AMNI) » Definitions » Return-on-Tangible-Asset

Amniotics AB (OSTO:AMNI) Return-on-Tangible-Asset : -135.74% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Amniotics AB Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Amniotics AB's annualized Net Income for the quarter that ended in Dec. 2023 was kr-23.30 Mil. Amniotics AB's average total tangible assets for the quarter that ended in Dec. 2023 was kr17.17 Mil. Therefore, Amniotics AB's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -135.74%.

The historical rank and industry rank for Amniotics AB's Return-on-Tangible-Asset or its related term are showing as below:

OSTO:AMNI' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -152.97   Med: -103.72   Max: -78.45
Current: -101.57

During the past 5 years, Amniotics AB's highest Return-on-Tangible-Asset was -78.45%. The lowest was -152.97%. And the median was -103.72%.

OSTO:AMNI's Return-on-Tangible-Asset is ranked worse than
79.17% of 1546 companies
in the Biotechnology industry
Industry Median: -40.51 vs OSTO:AMNI: -101.57

Amniotics AB Return-on-Tangible-Asset Historical Data

The historical data trend for Amniotics AB's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amniotics AB Return-on-Tangible-Asset Chart

Amniotics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
-78.45 -98.42 -103.72 -126.33 -152.97

Amniotics AB Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -188.54 -147.51 -130.65 -149.86 -135.74

Competitive Comparison of Amniotics AB's Return-on-Tangible-Asset

For the Biotechnology subindustry, Amniotics AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amniotics AB's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amniotics AB's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Amniotics AB's Return-on-Tangible-Asset falls into.



Amniotics AB Return-on-Tangible-Asset Calculation

Amniotics AB's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-30.87/( (22.366+17.996)/ 2 )
=-30.87/20.181
=-152.97 %

Amniotics AB's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-23.304/( (16.341+17.996)/ 2 )
=-23.304/17.1685
=-135.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Amniotics AB  (OSTO:AMNI) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Amniotics AB Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Amniotics AB's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Amniotics AB (OSTO:AMNI) Business Description

Traded in Other Exchanges
Address
Scheelevagen 2, Lund, SWE, 223 63
Amniotics AB is a biopharma company focusing on mesenchymal stem cells from amniotic fluid. It provides a novel platform for the production of medically superior mesenchymal stem cells including ethical and medically sound bio-banking opportunities for the newborn.

Amniotics AB (OSTO:AMNI) Headlines

From GuruFocus

American Noble Gas Announces Ticker Symbol Change

By Stock market mentor Stock market mentor 01-23-2023